Zealand Pharma A/S

    Jurisdiction
    Denmark
    LEI
    549300ITBB1ULBL4CZ12
    ISIN
    DK0060257814 (ZEAL.CO)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    InsiderPie Expert Score
    50 / 100
    Even with peer group:
    51 / 100
    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    7 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    4 / 7

    Profile

    Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. Read full profile

    Fundamentals

    Net revenue
    €1.22B
    Gross margin
    100.1%
    EBIT
    €962.26M
    EBIT margin
    78.8%
    Net income
    €895.04M
    Net margin
    73.3%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €652.25M -46.6% €128.01M -85.7%
    N/A N/A
    N/A N/A

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    No insider transactions in the last 90 days. View older insider transactions

    Earnings Calls

    Earnings Calls

    Latest earnings call: August 14, 2025 (Q2 2025)

    Add to watchlist

    Notifications